Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $12.23 billion. The enterprise value is $11.77 billion.
| Market Cap | 12.23B |
| Enterprise Value | 11.77B |
Important Dates
The last earnings date was Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.34 million shares outstanding. The number of shares has decreased by -2.27% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 63.34M |
| Shares Change (YoY) | -2.27% |
| Shares Change (QoQ) | -0.34% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 61.48M |
Valuation Ratios
The trailing PE ratio is 1.13 and the forward PE ratio is 13.67.
| PE Ratio | 1.13 |
| Forward PE | 13.67 |
| PS Ratio | 3.90 |
| Forward PS | 0.46 |
| PB Ratio | 15.94 |
| P/TBV Ratio | 26.51 |
| P/FCF Ratio | 10.76 |
| P/OCF Ratio | 10.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.89, with an EV/FCF ratio of 10.36.
| EV / Earnings | 10.35 |
| EV / Sales | 3.76 |
| EV / EBITDA | 10.89 |
| EV / EBIT | 11.36 |
| EV / FCF | 10.36 |
Financial Position
The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.34 |
| Quick Ratio | 5.32 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.02 |
| Interest Coverage | 59.10 |
Financial Efficiency
Return on equity (ROE) is 41.53% and return on invested capital (ROIC) is 22.95%.
| Return on Equity (ROE) | 41.53% |
| Return on Assets (ROA) | 20.66% |
| Return on Invested Capital (ROIC) | 22.95% |
| Return on Capital Employed (ROCE) | 122.66% |
| Revenue Per Employee | $1.17M |
| Profits Per Employee | $423,920 |
| Employee Count | 2,682 |
| Asset Turnover | 1.00 |
| Inventory Turnover | 16.95 |
Taxes
In the past 12 months, Genmab has paid $190.10 million in taxes.
| Income Tax | 190.10M |
| Effective Tax Rate | 14.32% |
Stock Price Statistics
The stock price has decreased by -30.89% in the last 52 weeks. The beta is 0.90, so Genmab's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -30.89% |
| 50-Day Moving Average | 20.26 |
| 200-Day Moving Average | 22.50 |
| Relative Strength Index (RSI) | 47.69 |
| Average Volume (20 Days) | 1,446,487 |
Short Selling Information
The latest short interest is 2.39 million, so 0.33% of the outstanding shares have been sold short.
| Short Interest | 2.39M |
| Short Previous Month | 2.02M |
| Short % of Shares Out | 0.33% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.24 |
Income Statement
In the last 12 months, Genmab had revenue of $3.14 billion and earned $1.14 billion in profits. Earnings per share was $17.68.
| Revenue | 3.14B |
| Gross Profit | 2.99B |
| Operating Income | 1.04B |
| Pretax Income | n/a |
| Net Income | 1.14B |
| EBITDA | 1.08B |
| EBIT | 1.04B |
| Earnings Per Share (EPS) | $17.68 |
Balance Sheet
The company has $467.42 million in cash and $20.72 million in debt, giving a net cash position of $446.70 million or $7.05 per share.
| Cash & Cash Equivalents | 467.42M |
| Total Debt | 20.72M |
| Net Cash | 446.70M |
| Net Cash Per Share | $7.05 |
| Equity (Book Value) | 767.34M |
| Book Value Per Share | 12.11 |
| Working Capital | 475.39M |
Cash Flow
In the last 12 months, operating cash flow was $1.14 billion and capital expenditures -$28.25 million, giving a free cash flow of $1.14 billion.
| Operating Cash Flow | 1.14B |
| Capital Expenditures | -28.25M |
| Free Cash Flow | 1.14B |
| FCF Per Share | $17.95 |
Margins
Gross margin is 95.38%, with operating and profit margins of 33.05% and 36.26%.
| Gross Margin | 95.38% |
| Operating Margin | 33.05% |
| Pretax Margin | 42.33% |
| Profit Margin | 36.26% |
| EBITDA Margin | 34.49% |
| EBIT Margin | 33.05% |
| FCF Margin | 36.26% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.27% |
| Shareholder Yield | 2.27% |
| Earnings Yield | 9.29% |
| FCF Yield | 9.29% |
Analyst Forecast
The average price target for Genmab is $39.17, which is 96.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.17 |
| Price Target Difference | 96.54% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 11.89% |
| EPS Growth Forecast (5Y) | 7.41% |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 58.55 and a Piotroski F-Score of 4.
| Altman Z-Score | 58.55 |
| Piotroski F-Score | 4 |